Article Text

Download PDFPDF
Peroxisome Proliferator-Activated Receptor α L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis
  1. Hasibe Verdi,
  2. Elif Sare Koytak,
  3. Oğuz Önder,
  4. Ayça Arslan Ergül,
  5. Kubilay Cinar,
  6. Ramazan Idilman,
  7. Esra Erden,
  8. Abdurrahman Mithat Bozdayi,
  9. Cihan Yurdaydin,
  10. Özden Uzunalimoglu,
  11. Hakan Bozkaya
  1. From the Institute of Hepatology (H.V., A.A.E., A.M.B., C.Y., O.U., H.B.), Department of Gastroenterology (E.S.K., O.O., K.C., R.I., A.M.B., C.Y., H.B.), School of Medicine, and Department of Pathology (E.E.), School of Medicine, Ankara University, Ankara, Turkey.
  1. Address correspondence to: Dr. Hakan Bozkaya, Department of Gastroenterology, School of Medicine, Ankara University, Tip Fakultesi Hastanesi, 06100 Dikimevi, Ankara, Turkey; e-mail: Hakan.Bozkaya{at}


Background Peroxisome proliferator-activated receptor α (PPARα) plays important roles in lipid metabolism. A recently discovered L162V polymorphism of the PPARα gene is associated with enhanced transcriptional activity. In this study, the frequency of L162V was investigated in nonalcoholic steatohepatitis (NASH) and genotype 1 hepatitis C virus (HCV)-related liver steatosis.

Methods Seventy-two NASH and 141 HCV-infected patients (54 with steatosis, 87 without steatosis) and 119 healthy controls were included. L162V polymorphism of the PPARα gene was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).

Results PCR and RFLP analysis of the related gene segment was successful in 93%, 96%, and 100% of NASH and HCV-infected patients and controls, respectively. The frequency of the L162V polymorphism was similar in the NASH and HCV-infected patients and controls (5.9%, 3.6%, and 2.5%, respectively). No difference in the frequency of this polymorphism was observed in HCV-infected patients with or without significant liver steatosis. L162V was not associated with obesity, type 2 diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia.

Conclusions Neither NASH nor genotype 1 HCV-related liver steatosis seems to be associated with the PPARα L162V polymorphism. This polymorphism may have no association with the presence of type 2 diabetes mellitus, obesity, or various blood lipid alterations in NASH and HCV-infected patients.

Key Words
  • peroxisome proliferator-activated receptor α
  • L162V
  • polymorphism
  • fatty liver
  • nonalcoholic steatohepatitis
  • hepatitis C virus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.